Clinical Research Directory
Browse clinical research sites, groups, and studies.
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Sponsor: The Affiliated Hospital of Xuzhou Medical University
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
Official title: A Clinical Study Evaluating the Safety and Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2025-03-18
Completion Date
2028-09
Last Updated
2025-09-04
Healthy Volunteers
No
Interventions
UCAR-T cells
UCAR-T cells will be administered intravenously as per the schedule specified in the protocol.
Cyclophosphamide
Cyclophosphamide will be administered intravenously.
Fludarabine
Fludarabine will be administered intravenously.
Locations (1)
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China